Olema Pharmaceuticals, Inc. OLMA 深 滬
已收盤 01-09 16:00:00 美东时间
28.08
+2.510
+9.82%
華盛通- 最 高28.20
- 今 開26.01
- 成交量 254.28万股
- 最 低 25.785
- 昨 收 25.57
- 總市值 22.09亿
- 52周最高 36.2591
- 市盈率 靜 --
- 換手率 3.23%
- 52周最低 2.86
- 委 比 -79.95%
- 總股本 7865.99万
- 歷史最高 60.27
- 量 比 1.92
- 振 幅 9.44%
- 歷史最低 2.00
- 每 手 1
- 風險率 7.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
UBS Initiates Coverage On Olema Pharmaceuticals with Buy Rating, Announces Price Target of $45
UBS analyst Michael Yee initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces Price Target of $45.
01-08 04:25
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
Olema Pharmaceuticals, Inc. announced that its CEO, Sean P. Bohen, M.D., Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2025. The presentation will be available via live webcast and recording on Olema’s Investor Relations website. Olema focuses on developing targeted therapies for breast cancer, with its lead candidate, palazestrant, in Phase 3 trials, and OP-3136 in Phase 1 testing. The company is headqua...
01-05 12:00
美股周涨跌榜 | 特朗普媒体科技集团周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%
DJT周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%，本周首挂上市，为年内全球最大规模IPO；爱美医疗周涨34.4%，获拜玛林制药48亿美元收购>>
2025-12-20 09:40
美股牛股 | KYTX大涨超23%，Miv-cel临床试验取得积极成果；以星航运涨近9%，获瑞士航运集团收购要约
KYTX大涨超23%，Miv-cel临床试验取得积极成果；IMNM涨近16%，实验性药物晚期临床试验达主要终点；以星航运涨近9%，获瑞士航运集团收购要约>>
2025-12-16 19:53
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $38
Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $26 to $38.
2025-12-12 01:27
Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite falling more than 100 points ...
2025-12-10 23:41
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer, has granted stock options to two new employees for a total of 65,000 shares, effective December 1, 2025. The stock options vest over four years and have an exercise price of $27.95 per share, aligned with Nasdaq’s inducement rules. These awards were approved under the Company's 2022 Inducement Plan. Olema is advancin...
2025-12-02 21:30
